


PROGRAM



10th International Symposium Biological Therapy of Cancer from Disease to Targeted Therapy

co-organised by
Biotherapy Development Association (BDA)
European Society for Medical Oncology (ESMO)
National Cancer Institute (NCI)
Tumorzentrum Rhein-Main e.V.
Tumorzentrum München



www.bdaoncology.org

Munich, Germany
September 8 – 10, 2010

BTOCC10





10th International Symposium Biological Therapy of Cancer from Disease to Targeted Therapy

Due to the exciting developments in molecular biology during the past decade and our increasing understanding of the mechanisms relevant to the cancer formation, we are experiencing a transition from general to individualized, target-oriented therapy. This has a strong impact on the development paradigm of cancer therapeutics.

To date, breakthroughs have mainly been achieved with therapeutic monoclonal antibodies or signal transduction inhibitors. Numerous other classes of biological agents are in clinical development and are expected to revolutionize cancer therapy.

The 10th International Congress on "Biological Therapy of Cancer" will again be held in September, 8th – 10th 2010 under the auspices of the Tumor Center Munich. Like the previous meetings, BTOC-10 will focus on the clinical development of a broad spectrum of anticancer agents with an emphasis on immunomodulatory agents such as monoclonal antibodies and vaccines apart from gene therapeutic approaches.

Call for Abstracts

Free communications and poster sessions are one of the conference highlights. All participants are invited to submit abstracts for poster presentations. A limited number will be selected for oral presentation. All accepted abstracts will be **published in memo – Magazine of European Medical Oncology**.

Deadline: prolonged to August 15, 2010

Please submit an abstract online after registering for the conference or send it to abstracts@bdaoncology.org. The best posters will receive a poster award!

Registration

Please visit www.bdaoncology.org

Registration fee (Euro)

	full	ESMO members	physicians and scientists in training, students
Early Registration ¹	250,-	150,-	75,-
Late Registration	350,-	250,-	100,-

Members of Tumor Center Munich or Rhein-Main may participate at no charge.

¹payment received before July 30, 2010

Congress Location

Ludwig-Maximilians-Universität München
Lecture Hall, Institute for Chemistry and und Pharmacy
Butenandtstr. 5-13, 81377 Munich

Exhibition

An industrial exhibition will accompany the conference. There will be additional possibilities for industry to actively participate in the conference (e.g. advertisement in the printed final program, sponsoring of the congress bag, etc.). Please contact: btoc@bdaoncology.org for information and registration.

Wednesday, September 8, 2010

- 11.00 a.m. **Start of Registration**
- 12.30 – 12.40 p.m. **Welcome and Introduction**
- 12.40 – 2.45 p.m. **MONOCLONAL ANTIBODIES FOR PERSONALIZED MEDICINE**
CHAIR: H. Chen, H. Zwierzina
- 12.40 – 1.05 p.m. Monoclonal antibodies – future challenges
H. Chen, Bethesda
- 1.05 – 1.30 p.m. Predictive value of Fc-receptor polymorphism on ADCC
M. Liljefors, Stockholm
- 1.30 – 1.55 p.m. Monitoring antibody-based therapy of colorectal cancer
A. Bardelli, Torino
- 1.55 – 2.20 p.m. Clinical development of insulin-like growth factor antibodies
S. DiCosimo, Barcelona
- 2.20 – 2.45 p.m. BiTE antibodies for cancer immunotherapy
P. Bauerle, Munich
- 2.45 – 4.00 p.m. **POSTER SESSION / COFFEE BREAK**

ESMO-MORA accreditation:

This Partnership Meeting has been accredited with 16 cat. 1 ESMO-MORA points by the E-Learning and CME Working Group.

Wednesday, September 8, 2010 - Late Afternoon

- 4.00 – 6.00 p.m. **COMBINATION THERAPY – PRECLINICAL ASPECTS**
CHAIR: G. Folprecht, t.b.c.
- 4.00 – 4.25 p.m. Preclinical biomarker discovery – application of new technologies
G. C. Murray, Nottingham
- 4.25 – 4.50 p.m. Reevaluating the role of proteomics in oncology
J. Loeffler-Ragg, Innsbruck
- 4.50 – 5.15 p.m. Investigation of cancer drug mode of action in presurgical studies
G. Folprecht, Dresden
- 5.15 – 5.40 p.m. The need for combining targeted therapies – taking on new challenges
F. Ciardiello, Naples
- 5.40 – 5.50 p.m. Nodular growing tumor cells for the identification of innovative target combinations for anti-cancer therapies
C. H. Wagner et al, Bonn
- 5.50 – 6.00 p.m. Evaluation of the human oncogenic factor YB-1 as a target in the eradication of glioma initiating cells by virotherapy in an orthotopic mouse model
K. Mantwill et al, Munich
- 7.30 p.m. **Welcome Reception**

For further details, program updates, registration and abstract submission please visit the conference homepage

www.bdaoncology.org

Thursday, September 9, 2010 - Morning

- 9.00 – 11.35 a.m. **COMBINATION THERAPY – CLINICAL ASPECTS**
CHAIR: L. Bergmann, F. Cardiello
- 9.00 – 9.25 a.m. Targeting the PI3K-AKT and Raf-MEK-ERK pathways for the treatment of cancer - novel-novel development
T. Bogenrieder, London
- 9.25 – 9.50 a.m. Preclinical activity of type II CD20 antibody GA101 as single agent and in combination with chemotherapy or targeted agents
C. Klein, Schlieren
- 9.50 – 10.15 a.m. Preclinical evaluation of a suitable combination of trifunctional antibodies with chemotherapy
J. Atz, Munich
- 10.15 – 10.45 a.m. **COFFEE BREAK**
CHAIR: W. Hilbe, C. Swanton
- 10.45 – 11.10 a.m. Combination therapy with everolimus and trastuzumab
G. Jerusalem, Liège
- 11.10 – 11.35 a.m. Everolimus in combination with octreotide and SOM230
M. Peeters, Edegem
- 11.35 – 12.35 a.m. **DEVELOPMENTS IN MicroRNA AND RNA INTERFERENCE**
CHAIR: W. Hilbe, C. Swanton
- 11.35 – 12.00 p.m. Causes and consequences of microRNA dysregulation in cancer
t.b.c.
- 12.00 – 12.25 p.m. Predictive and prognostic biomarker discovery using functional RNA interference approaches
C. Swanton, London
- 12.25 – 12.35 p.m. ppp-siRNA combining TGF-beta silencing, RIG-I activation and apoptosis induction effectively induces antitumor response in murine pancreatic carcinoma
J. Ellmermeier, Munich
- 1.35 – 2.00 p.m. **LUNCH**

Thursday, September 9, 2010 - Afternoon

- 2.00 – 5.55 p.m. **BDA Immunotherapy Working Group together with iSBTc THE INFLUENCE OF MALIGNANT TUMORS ON THE IMMUNE SYSTEM I**
CHAIR: L. Hakansson, S. Khleif
- 2.00 – 2.10 p.m. Welcome and introduction (a short overview, immunosuppression at different levels)
L. Hakansson, Linköping
- 2.10 – 2.35 p.m. **KEY NOTE LECTURE: The immunoediting model**
A. Dalglish, London
- 2.35 – 3.00 p.m. Recruitment of inflammatory cells – role of chemokines
T. Gajewski, Chicago
- 3.00 – 3.25 p.m. Regulation of the migration of inflammatory cells
N. Hogg, London
- 3.25 – 3.50 p.m. The role of oxidative stress in host-anti-tumor immunity
R. Kiessling, Stockholm
- 3.50 – 4.30 p.m. **COFFEE BREAK**
- 4.30 – 4.55 p.m. Hypoxia induced immunomodulation
L. Varesio, Genova
- 4.55 – 5.20 p.m. The effect of anti-VEGF therapy on cancer related immunosuppression
T. Osada, Durham
- 5.20 – 5.45 p.m. MHC class I abnormalities in tumors associated with altered IFN signal transduction and transcription factors
B. Seliger, Halle
- 5.45 – 5.55 p.m. CpG blocks immune suppression by myeloid-derived suppressor cells in tumor-bearing mice
C. Zoglmeier, Munich

Friday, September 10, 2010

- 9.00 – 10.40 a.m. **BDA Immunotherapy Working Group together with iSBTc**
THE INFLUENCE OF MALIGNANT TUMORS ON THE IMMUNE SYSTEM II
CHAIR: T.F.Gajewski, R. Kiessling
- 9.00 – 9.25 a.m. Fc-receptor mediated immune regulation in cancer
F.Nimmerjahn, Erlangen
- 9.25 – 9.50 a.m. Modulation of chemokine activity by tumor-derived proteases
M. Wolf, Bern
- 9.50 – 10.15 a.m. Therapeutic effect of antibodies directed against phosphatidyl serine
J. Shan, Tustin
- 10.15 – 10.40 a.m. Primary and secondary immunosuppression in cancer
L. Hakansson, Linköping
- 10.40 – 11.00 a.m. **COFFEE BREAK**
- 11.00 – 12.00 a.m. **PANEL DISCUSSION: Immunoregulation in cancer**
- 12.00 – 1.00 p.m. **LUNCH**

Travel and Young Scientist awards

If you are interested, please sign-up, activate your account and register online for the meeting. As soon as you have signed up, submit an abstract about your scientific work together with a short CV.

Alternatively, please send your abstract together with the CV to abstracts@bdaoncology.org.

After peer-reviewing of all submitted abstracts and CVs, the best scientists will be selected for the submitted awards and should present their scientific work at the poster presentation.

Friday, September 10, 2010 - Afternoon

- 1.00 – 3.05 p.m. **THERAPEUTIC CANCER VACCINES**
CHAIR: A. Dalglish, M.J.P. Welters
- 1.00 – 1.25 p.m. Cancer vaccine development strategies
S. Kleif, Bethesda
- 1.25 – 1.50 p.m. DNA vaccination in oncology: Current status, opportunities and perspectives
J.H. van den Berg, Herlev
- 1.50 – 2.15 p.m. Vaccination strategies in NSCLC
M. Falk, Darmstadt
- 2.15 – 2.40 p.m. Monitoring of cancer vaccine trials
M.J.P. Welters, Leiden
- 2.40 – 3.05 p.m. Sipuleucel-T (PROVENGE) – The first therapeutic active cellular immunotherapy for patients with minimal and asymptomatic castrate resistant prostate cancer
C. Pöhlein, Seattle
- 3.05 p.m. **End of meeting**

Organizing Committee

L. Bergmann, Germany

B. Fox, USA

L. Hakansson, Sweden

S. Khleif, USA

H. Mellstedt, Sweden

V. Nuessler, Germany

M. Scheulen, Germany

H. Zwierzina, Austria

Contact

BDA congress office | Eugen Preuss, MD
Tel. +43(0)512-579497 | Fax +43(0)512-579497-55

btoc@bdaoncology.org

